These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21476823)

  • 1. Cost-effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease.
    Adarkwah CC; Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Apr; 11(2):215-23. PubMed ID: 21476823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To treat or not to treat? Cost-effectiveness of ace inhibitors in non-diabetic advanced renal disease - a Dutch perspective.
    Adarkwah CC; Gandjour A; Akkerman M; Evers S
    Kidney Blood Press Res; 2013; 37(2-3):168-80. PubMed ID: 23689440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism.
    Vegter S; Perna A; Hiddema W; Ruggenenti P; Remuzzi G; Navis G; Postma MJ
    Pharmacogenet Genomics; 2009 Sep; 19(9):695-703. PubMed ID: 19696696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal effects of angiotensin-converting enzyme inhibitors that result in cost savings and improved patient outcomes.
    Swislocki AL; Siegel D
    Am J Manag Care; 2001 Mar; 7(3):283-95. PubMed ID: 11258145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany.
    Adarkwah CC; Gandjour A
    Int J Technol Assess Health Care; 2010 Jan; 26(1):62-70. PubMed ID: 20059782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor.
    Costa-Scharplatz M; van Asselt AD; Bachmann LM; Kessels AG; Severens JL
    Pharmacogenet Genomics; 2007 May; 17(5):359-68. PubMed ID: 17429318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.
    Golan L; Birkmeyer JD; Welch HG
    Ann Intern Med; 1999 Nov; 131(9):660-7. PubMed ID: 10577328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic analysis of angiotensin-converting enzyme inhibitors in type 2 diabetes: a Markov model.
    Campbell HM; Boardman KD; Dodd MA; Raisch DW
    Ann Pharmacother; 2007 Jul; 41(7):1101-10. PubMed ID: 17609233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The use of angiotensin-converting enzyme inhibitors in chronic diffuse kidney diseases].
    Kutyrina IM; Tareeva IE; Gerasimenko OI; Rogov VA; Miroshnichenko NG
    Ter Arkh; 1995; 67(5):20-3. PubMed ID: 7638769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal and cardiovascular effects of angiotensin-converting enzyme inhibitor plus angiotensin II receptor antagonist therapy in children with proteinuria.
    Lubrano R; Soscia F; Elli M; Ventriglia F; Raggi C; Travasso E; Scateni S; Di Maio V; Versacci P; Masciangelo R; Romero S
    Pediatrics; 2006 Sep; 118(3):e833-8. PubMed ID: 16923922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy.
    Clark WF; Churchill DN; Forwell L; Macdonald G; Foster S
    CMAJ; 2000 Jan; 162(2):195-8. PubMed ID: 10674051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H; Hayashi K; Saruta T
    J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
    Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease.
    Chrysostomou A; Becker G
    N Engl J Med; 2001 Sep; 345(12):925-6. PubMed ID: 11565535
    [No Abstract]   [Full Text] [Related]  

  • 15. Progression of renal disease--can it be reversed? The role of calcium channel blockers and angiotensin-converting enzyme inhibitors.
    Boner G
    Isr J Med Sci; 1996 Dec; 32(12):1217-21. PubMed ID: 9007157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients.
    van der Kleij FG; Navis GJ; Gansevoort RT; Heeg JE; Scheffer H; de Zeeuw D; de Jong PE
    Nephrol Dial Transplant; 1997; 12 Suppl 2():42-6. PubMed ID: 9269699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan.
    Sakamaki Y; Sasamura H; Ikeda S; Ikegami N; Saruta T
    Hypertens Res; 2006 May; 29(5):333-8. PubMed ID: 16832153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use of angiotensin-converting enzyme inhibitors in patients with renal impairment.
    Elliott HL
    Blood Press Suppl; 1994; 2():31-4. PubMed ID: 8061843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies.
    Ruggenenti P; Pagano E; Tammuzzo L; Benini R; Garattini L; Remuzzi G
    Kidney Int; 2001 Jan; 59(1):286-94. PubMed ID: 11135082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How should renin-angiotensin system blockade be applied in chronic kidney disease for optimal renal protection?
    Zhang X; Hou FF
    Chin Med J (Engl); 2007 Feb; 120(3):243-5. PubMed ID: 17355830
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.